These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

249 related articles for article (PubMed ID: 2493176)

  • 1. OKT3 salvage therapy in a quadruple immunosuppressive protocol in cadaveric renal transplantation.
    D'Alessandro AM; Pirsch JD; Stratta RJ; Sollinger HW; Kalayoglu M; Maki DG; Belzer FO
    Transplantation; 1989 Feb; 47(2):297-300. PubMed ID: 2493176
    [TBL] [Abstract][Full Text] [Related]  

  • 2. OKT3 for primary therapy of the first rejection episode in kidney transplants.
    Tesi RJ; Elkhammas EA; Henry ML; Ferguson RM
    Transplantation; 1993 May; 55(5):1023-9. PubMed ID: 8497875
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sequential antilymphocyte globulin/cyclosporine immunosuppression in cadaveric renal transplantation. Effect of duration of ALG therapy.
    Stratta RJ; D'Alessandro AM; Armbrust MJ; Pirsch JD; Sollinger HW; Kalayoglu M; Belzer FO
    Transplantation; 1989 Jan; 47(1):96-102. PubMed ID: 2643236
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Quadruple immunosuppression: comparison of OKT3 and Minnesota antilymphocyte globulin.
    Light JA; Khawand N; Aquino A; Ali A; Korb S
    Am J Kidney Dis; 1989 Nov; 14(5 Suppl 2):10-3. PubMed ID: 2510505
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Induction immunosuppression with antilymphocyte globulin or OKT3 in cadaver kidney transplantation. Results of a single institution prospective randomized trial.
    Hanto DW; Jendrisak MD; So SK; McCullough CS; Rush TM; Michalski SM; Phelan D; Mohanakumar T
    Transplantation; 1994 Feb; 57(3):377-84. PubMed ID: 8108873
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antilymphocyte globulins versus OKT3 as prophylactic treatment in highly sensitized renal transplant recipients.
    Vela C; Cristol JP; Chong G; Okamba A; Lorho R; Mion C; Mourad G
    Transpl Int; 1994; 7 Suppl 1():S259-62. PubMed ID: 11271219
    [TBL] [Abstract][Full Text] [Related]  

  • 7. OKT3 prophylaxis versus conventional drug therapy: single-center perspective, part of a multicenter trial.
    Kahana L; Narvarte J; Ackermann J; LeFor W; Weinstein S; Wright C; deQuesada A; Baxter J; Shires D
    Am J Kidney Dis; 1989 Nov; 14(5 Suppl 2):5-9. PubMed ID: 2510510
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prophylactic use of OKT3 in immunologic high-risk cadaver renal transplant recipients.
    Schroeder TJ; First MR; Mansour ME; Alexander JW; Penn I
    Am J Kidney Dis; 1989 Nov; 14(5 Suppl 2):14-8. PubMed ID: 2510506
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The use of OKT3 in cadaveric renal transplantation for rejection that is unresponsive to conventional anti-rejection therapy.
    Norman DJ; Barry JM; Bennett WM; Leone M; Henell K; Funnell B; Hubert B
    Am J Kidney Dis; 1988 Feb; 11(2):90-3. PubMed ID: 3124611
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A prospective randomized comparison of quadruple versus triple therapy for first cadaver transplants with immediate function.
    Slakey DP; Johnson CP; Callaluce RD; Browne BJ; Zhu YR; Roza AM; Adams MB
    Transplantation; 1993 Oct; 56(4):827-31. PubMed ID: 8212201
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Increased infections associated with the use of OKT3 for treatment of steroid-resistant rejection in renal transplantation.
    Oh CS; Stratta RJ; Fox BC; Sollinger HW; Belzer FO; Maki DG
    Transplantation; 1988 Jan; 45(1):68-73. PubMed ID: 3276066
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Predicting factors of long-term results of OKT3 therapy for steroid resistant acute rejection following cadaveric renal transplantation.
    Rostaing L; Chabannier MH; Modesto A; Rouzaud A; Cisterne JM; Tkaczuk J; Durand D
    Am J Nephrol; 1999; 19(6):634-40. PubMed ID: 10592356
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Delayed response to orthoclone OKT3 treatment for renal allograft rejection resistant to steroid and antilymphocyte globulin.
    Oh CS; Sollinger HW; Stratta RJ; Kalayoglu M; Belzer FO
    Transplantation; 1988 Jan; 45(1):65-7. PubMed ID: 3276065
    [TBL] [Abstract][Full Text] [Related]  

  • 14. OKT3 treatment of steroid-resistant renal allograft rejection.
    Thistlethwaite JR; Gaber AO; Haag BW; Aronson AJ; Broelsch CE; Stuart JK; Stuart FP
    Transplantation; 1987 Feb; 43(2):176-84. PubMed ID: 3544373
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Improved efficacy of basiliximab over antilymphocyte globulin induction therapy in paediatric renal transplantation.
    Clark G; Walsh G; Deshpande P; Koffman G
    Nephrol Dial Transplant; 2002 Jul; 17(7):1304-9. PubMed ID: 12105256
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antilymphocyte globulin versus OKT3 induction therapy in cadaveric kidney transplantation: a prospective randomized study.
    Grino JM; Castelao AM; Serón D; Gonzalez C; Galceran JM; Gil-Vernet S; Andrés E; Mestre M; Torras J; Alsina J
    Am J Kidney Dis; 1992 Dec; 20(6):603-10. PubMed ID: 1462990
    [TBL] [Abstract][Full Text] [Related]  

  • 17. OKT3 escalating dose regimens provide effective therapy for renal allograft rejection.
    Woodle ES; Bruce DS; Josephson M; Cronin D; Newell KA; Millis JM; Piper JB; O'Laughlin R; Thistlethwaite JR
    Clin Transplant; 1996 Aug; 10(4):389-95. PubMed ID: 8884115
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical experience with Muromonab-CD3 monoclonal antibody (OKT3) in heart transplantation.
    Macris MP; Frazier OH; Lammermeier D; Radovancevic B; Duncan JM
    J Heart Transplant; 1989; 8(4):281-7. PubMed ID: 2504894
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation of OKT3 monoclonal antibody and anti-thymocyte globulin in the treatment of steroid-resistant acute allograft rejection in pediatric renal transplants.
    Mochon M; Kaiser B; Palmer JA; Polinsky M; Flynn JT; Caputo GC; Baluarte HJ
    Pediatr Nephrol; 1993 Jun; 7(3):259-62. PubMed ID: 8518094
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prophylactic therapy for rejection after cardiac transplantation. A comparison of rabbit antithymocyte globulin and OKT3.
    Kirklin JK; Bourge RC; White-Williams C; Naftel DC; Thomas FT; Thomas JM; Phillips MG
    J Thorac Cardiovasc Surg; 1990 Apr; 99(4):716-24. PubMed ID: 2108282
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.